EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Pseudomonas aeruginosa biofilm exopolysaccharide composition on bacteriophage and bacteriophage-antibiotic combination activity

Sean R Van Helden iD, Callan R Bleick, Dana J Holger iD, Amer El Ghali, Jose Alexander, Keith S Kaye, Steven H Marshall, Laura J Rojas, Robert A Bonomo iD, Susan M Lehman iD, Michael J Rybak iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00925-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Sean R Van Helden und 10 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Biofilms, Pseudomonas aeruginosa, Anti-Bacterial Agents, Polysaccharides, Bacterial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug-resistant Pseudomonas aeruginosa is a leading cause of hospital-acquired infections, including medical device infections, partially due to the organism’s ability to produce biofilm on prosthetic material. Increased antibiotic tolerance of bacteria within biofilm, along with the increasing prevalence of infections caused by multidrug-resistant P. aeruginosa , including extensively drug-resistant phenotypes, results in scenarios where conventional antibiotics may fail to effectively treat these infections. Bacteriophage (phage) therapy is a promising alternative to conventional antimicrobial therapy that can provide potent antibiofilm activity, particularly when combined with antibiotics. The impact of P. aeruginosa biofilm phenotype on the efficacy of phage-antibiotic combinations remains unclear. We characterized the biofilms of a panel of 10 clinical and two laboratory P. aeruginosa isolates by determining the minimum biofilm inhibitory concentrations, biofilm production capabilities, and phage activity. Furthermore, we quantified the exopolysaccharide content of P. aeruginosa strains PAO1 and PA14 and confirmed they produced Class II and Class I biofilm, respectively. We then selected a triple-phage cocktail with broad activity across all P. aeruginosa strains for evaluation of antibiofilm activity against PAO1 and PA14 in vitro . Through spectrophotometric growth suppression and time-kill analyses, we found the triple-phage cocktail + ciprofloxacin to be more efficacious in biofilm eradication than either modality alone. Phage 109 displayed potent antibiofilm activity against both strains irrespective of planktonic activity, whereas phages E2005-C and EM-T3762627-2_AH displayed distinct antibiofilm activity based on biofilm phenotype. These data warrant further investigation into the impact of P. aeruginosa biofilm phenotype on phage antibiofilm activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiofilmsPseudomonas aeruginosaAnti-Bacterial AgentsPolysaccharides, BacterialBacteriophagesPseudomonas PhagesMicrobial Sensitivity TestsPhage TherapyHumansDrug Resistance, Multiple, BacterialPseudomonas Infections

Stichwörter der Autor:innen

DTRMDRPDRPseudomonas aeruginosaXDRantimicrobial resistancebiofilmbiofilm matrixmedical device infectionsmultidrug resistance

Substanzen

Anti-Bacterial AgentsPolysaccharides, Bacterial

Autor:innen und Institutionen

  • Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
  • Department of Pharmacy Practice, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.
  • University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
  • Department of Microbiology, Virology and Immunology, AdventHealth Central Florida, Orlando, Florida, USA.
  • Department of Medicine, Rutgers Robert Wood Johnsons Medical School, New Brunswick, New Jersey, USA.
  • Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.

ORCID-Profile: Sean R Van Helden, Dana J Holger, Robert A Bonomo, Susan M Lehman, Michael J Rybak

Förderung

  • NCI NIH HHS

Zitieren

APA

Van Helden, S. R., Bleick, C. R., Holger, D. J., El Ghali, A., Alexander, J., Kaye, K. S., Marshall, S. H., Rojas, L. J., Bonomo, R. A., Lehman, S. M., & Rybak, M. J. (2026). Impact of Pseudomonas aeruginosa biofilm exopolysaccharide composition on bacteriophage and bacteriophage-antibiotic combination activity. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00925-25

Vancouver

Van Helden SR, Bleick CR, Holger DJ, El Ghali A, Alexander J, Kaye KS, et al. Impact of Pseudomonas aeruginosa biofilm exopolysaccharide composition on bacteriophage and bacteriophage-antibiotic combination activity. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00925-25

BibTeX
@article{VanHelden2026,
  author = {Van Helden, Sean R and Bleick, Callan R and Holger, Dana J and El Ghali, Amer and Alexander, Jose and Kaye, Keith S and Marshall, Steven H and Rojas, Laura J and Bonomo, Robert A and Lehman, Susan M and Rybak, Michael J},
  title = {Impact of Pseudomonas aeruginosa biofilm exopolysaccharide composition on bacteriophage and bacteriophage-antibiotic combination activity},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00925-25}
}
Kostenlos starten →